melbourne meeting, page-10

Cgt, I remember NIH only funding drugs at Phase II but if Trius have funding in preclinical, not sure why Biota can't.

RSV Phase I early 2013, maybe they will try and secure funding then but I guess all other drugs have been put on the backburner to focus on LANI.

I did ask PC about funding for RSV and other drugs and he said they would consider looking into it.

I feel PC has done a great job with the pipeline of drugs we have, non-dilutive funding, great results with LANI (he sounded quite positive with the Inavir prevention study results which was quite unlike him :) and HRV too so some credit must be given though frustration with the SP is understandable.